PENTOXIL |
TRENTAL |
OXPENTIFYLLINE |
C04AD03 |
BL-191 |
PENTOXIFYLLINE |
NEOTREN MR |
TRENTAL 100 |
NSC-637086 |
TRENTAL 400 |
PENTOXIFILINA |
PENTOXIFYLLIN |
TRENTAL® |
PENTOXIFYLLINUM |
chemidplus:6493-05-6 |
pubchem.compound:4740 |
drugbank:00806 |
rxcui:8013 |
chembl:CHEMBL628 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | for treatment of amyotrophic lateral sclerosis (ALS) |
Year of Approval | 1984 |
Drug Class | hemorrheologic agents |
Drug Class | platelet aggregation inhibitors |
Drug Categories | radiation-protective agents |
Drug Categories | purine derivatives |
Drug Categories | antiplatelet agents |
Drug Categories | blood viscosity reducer |
Drug Categories | compounds used in a research, industrial, or household setting |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | drugs for obstructive airway diseases |
Drug Categories | drugs that are mainly renally excreted |
Drug Categories | hematologic activity alteration |
Drug Categories | hemorrheologic agents |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | phosphodiesterase 5 inhibitors |
Drug Categories | vasodilating agents |
Drug Categories | xanthine derivatives |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
Trial Name | pentoxifylline, EHT0201 |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Trial Name | pentoxifylline, EHT0201 |
Novel drug target | Established target |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | pentoxifylline, EHT0201 |
Novel drug target | Established target |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Adenosine A2 receptor antagonist |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
antagonist (inhibitory) |
Trial Name | pentoxifylline, EHT0201 |
Novel drug target | Established target |
antagonist (inhibitory) |
Mechanism of Interaction | Adenosine A2 receptor antagonist |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 3',5'-cyclic phosphodiesterase inhibitor |
Direct Interaction | yes |
PENTOXIFYLLINE | DrugBank Drug Name |
6493-05-6 | CAS Number |
Agapurin | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
PENTOXIFYLLINE | Primary Drug Name |
Drug Class | platelet aggregation inhibitors |
Drug Class | hemorrheologic agents |
Year of Approval | 1984 |
Drug Indications | for treatment of amyotrophic lateral sclerosis (ALS) |
Drug Class | Small Molecule |
FDA Approval | approved |
C733 | NCI drug code |
D09QEI | TTD Drug ID |
PENTOXIFYLLINE | GuideToPharmacology Ligand Name |